Serum cathelicidin antimicrobial peptide (CAMP) levels are significantly reduced in HCC patients, and CAMP supplementation effectively inhibits HCC cell proliferation, suggesting its potential as a diagnostic biomarker (72). The gene discussed is CAMP; the disease is hepatocellular carcinoma.